Clinical trial · Interventional
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
A Real World Study of Efficacy and Safety for Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
NCT03377842CI-TRIAL-00030848unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and to explore factors associated with efficacy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| apatinib and FOLFOX regimen | Drug | — | UNRESOLVED |
| FOLFOX regimen | Drug | FOLFOX Regimen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- FOLFOX regimen
- description
- FOLFOX regime alone.
- interventionNames
- Drug: FOLFOX regimen
- type
- EXPERIMENTAL
- label
- Apatinib and FOLFOX regimen
- description
- Apatinib combine with FOLFOX regimen.
- interventionNames
- Drug: apatinib and FOLFOX regimen
Primary outcomes (2)
- measure
- R0 ,R1 or R2 resection
- timeFrame
- at least 4-6 weeks after the end of chemotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 18 years or older. * Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum; * Stage TxNxM1 (truly metastatic disease) with liver metastases only. * Patients should be voluntary to the trial and provide with signed informed consent. * The researchers believe patients can benefit from the study. Exclusion Criteria: * Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories. * Pregnant or lactating women * Patients with Apatinib contraindications * Patients of doctors considered unsuitable for the trial
References
Publications (1)
- BACKGROUNDLi J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16. PMID 26884585